NYSEMKT: IBIOIbio Inc Stock
$1.98+0.17 (+9.39%)
Updated May 17, 2024
IBIO Price
$1.98
Fair Value Price
N/A
Market Cap
$17.07M
52 Week Low
$1.02
52 Week High
$19.20
P/E
-0.41x
P/B
0.69x
P/S
301.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$50.00k
Earnings
-$23.16M
Gross Margin
100%
Operating Margin
-46,066%
Profit Margin
-46,324%
Debt to Equity
1.02
Operating Cash Flow
-$19M
Beta
0.28
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IBIO Overview
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The firm is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The firm's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The firm is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The firm's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IBIO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IBIO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IBIO is good value based on its book value relative to its share price (0.69x), compared to the US Biotechnology industry average (6.01x)
P/B vs Industry Valuation
IBIO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IBIO due diligence checks available for Premium users.
Be the first to know about important IBIO news, forecast changes, insider trades & much more!
IBIO News
Valuation
IBIO price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.41x
Industry
8.47x
Market
30.97x
IBIO price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.69x
Industry
6.01x
IBIO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IBIO's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.2M
Profit Margin
0%
IBIO's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IBIO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$50.2M
Liabilities
$25.3M
Debt to equity
1.02
IBIO's short-term assets ($36.14M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IBIO's short-term assets ($36.14M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IBIO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IBIO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.7M
Investing
$1.0M
Financing
$5.0M
IBIO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IBIO vs Biotech Stocks
Ibio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.